Floatz logo

Trastuzumab Emtansine

Breast Adenocarcinoma

Academic and Community Cancer Research Unitedantibody_drug_conjugatePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

25 Active assets in the Breast Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 3BB
Inno-206
Virginia Commonwealth University
Phase 3BB
Letrozole
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 4BB
TRASTUZUMAB
Academic and Community Cancer Research United
Phase 3BB
Carboplatin
Genmab
Phase 3BB

View all 50 →

Same molecule, other indications

Trastuzumab Emtansine is also rated in:

Breast Inflammatory CarcinomaDormant
BB
Indicative ·
67 / 100
View asset →
breast cancerDormant
BB
Indicative ·
66 / 100
View asset →
breast carcinomaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →